Slow market acceptance of CERAMENT
Revenue depends on surgeons and hospitals adopting a new orthopedic treatment standard.
- Scope
- Trauma, Foot & Ankle, Revision Arthroplasty, Spine
- Materiality
- high
Bonesupport Holding
BONESUPPORT Holding AB is a Swedish parent company for a medical technology group focused on orthobiologics. The group develops and commercializes injectable bioceramic bone graft substitutes under the CERAMENT platform for use in orthopedic procedures, with sales concentrated in the US and Europe.
143
5.13
3.90
| % | |
|---|---|
| CERAMENT bone graft substitutes | 90% Injectable bioceramic bone graft products used to fill bone voids and remodel into host bone. |
| Antibiotic-eluting products | 70% CERAMENT G and CERAMENT V products designed for bone infection and contaminated cases. |
| Non-antibiotic bone void filler | 10% CERAMENT BVF used in orthopedic reconstruction where drug elution is not required. |
| Commercial and clinical support | 10% Training, evidence generation, and surgeon support that help adoption of CERAMENT. |
BONESUPPORT sells primarily to hospitals, orthopedic surgeons, and healthcare systems that treat bone defects,...
- Hospitals and surgical centersprimary
Buy CERAMENT for orthopedic procedures involving bone voids, trauma, and infection management.
- Orthopedic surgeonsprimary
Use the products in surgery and influence adoption based on clinical outcomes and evidence.
- Pediatric hospitalssecondary
Access CERAMENT through OrthoPediatrics for children’s orthopedic cases.
- Distributors and agentssecondary
Purchase or facilitate sales in selected markets to extend geographic reach and coverage.
BONESUPPORT is headquartered in Lund, Sweden and operates through subsidiaries across Europe and the US...
- •Headquartered in Lund, Sweden with a Swedish parent company structure
- •Core commercial markets are the US and major European orthopedic markets
- •Own sales teams in Germany, the UK, Sweden, Denmark and Benelux
- •Hybrid model in Australia, Canada, Italy, Norway, Spain and South Africa
- •Specialist distributors cover other European and rest-of-world markets
BONESUPPORT’s strategy centers on expanding CERAMENT adoption in prioritized orthopedic segments, especially Foot &...
01
Segment focus in orthopedic proceduresshort-term
Concentrating on high-value procedure areas improves sales efficiency and clinical relevance.
02
Launch and expand in Spinemedium-term
Spine extends the CERAMENT platform into another large orthopedic use case.
03
Evidence generation and medical educationmedium-term
Clinical publications and health-economic data support surgeon adoption and reimbursement discussions.
BONESUPPORT is exposed to adoption risk because its products depend on surgeon acceptance, clinical evidence, and...
Regulatory and product approval risk
Medical device and combination-product requirements can delay or block launches.
- Materiality
- high
Product liability and insurance risk
Implantable orthopedic products can create claims if outcomes or safety are challenged.
- Materiality
- high
Intellectual property risk
CERAMENT depends on patents and protection against competing products or disputes.
- Materiality
- medium
Foreign exchange risk
Revenues and expenses are denominated mainly in USD, GBP and EUR versus SEK reporting.
- Scope
- USD, GBP, EUR
- Materiality
- high
Tariff and trade risk
US import tariffs can increase cost of goods and reduce segment economics.
- Scope
- United States imports
- Materiality
- medium
Revenue recognition and channel assessment
Sales commissions and fees, revenue timing
Right of return provisions
Revenue and provisions
Share-based remuneration and derivatives
Operating expenses and financial items
Lease accounting
Balance sheet and depreciation/interest expense
Tax loss carryforwards and receivables
Tax assets and impairment allowances
: 11/08/2026